Pace Elisabetta, Ferraro Maria, Bruno Andreina, Chiappara Giuseppina, Bousquet Jean, Gjomarkaj Mark
Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy.
J Asthma. 2011 May;48(4):387-92. doi: 10.3109/02770903.2011.561512. Epub 2011 Mar 11.
Severe asthma is characterized by inadequate symptom control and by high rate of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized monoclonal anti-IgE, provides a new therapeutic strategy in severe allergic asthma.
This study was aimed to assess whether long-term treatment with omalizumab improved clinical control in severe asthmatics.
We investigated omalizumab effects on asthma outcomes evaluating seven severe allergic asthmatic patients who were treated for 7 years with add-on omalizumab. Number of exacerbations, use of antibiotics, additional asthma medications (systemic steroids, nebulized steroids and bronchodilators), and spirometry were analyzed before and after omalizumab treatment.
Omalizumab was well tolerated by all the studied patients. It improved FEV1 and FEV1/FVC ratio and reduced symptom score, asthma exacerbations, use of antibiotics, and use of nebulized steroids, bronchodilators, and oral corticosteroids. These effects were evident after 4 years of treatment and more pronounced after 7 years of treatment.
This study underlines the utility of a long-term treatment with omalizumab to improve asthma clinical outcomes in severe asthmatics.
重度哮喘的特征是症状控制不佳，且尽管使用高剂量类固醇，炎症发生率仍很高。奥马珠单抗是一种重组人源化单克隆抗IgE抗体，为重度过敏性哮喘提供了一种新的治疗策略。
本研究旨在评估奥马珠单抗长期治疗是否能改善重度哮喘患者的临床控制情况。
我们通过评估7例接受奥马珠单抗附加治疗7年的重度过敏性哮喘患者，研究了奥马珠单抗对哮喘转归的影响。分析了奥马珠单抗治疗前后的加重次数、抗生素使用情况、其他哮喘药物（全身用类固醇、雾化吸入类固醇和支气管扩张剂）的使用情况以及肺功能测定结果。
所有研究患者对奥马珠单抗耐受性良好。它改善了第一秒用力呼气容积（FEV1）和FEV1/用力肺活量（FVC）比值，降低了症状评分、哮喘加重次数、抗生素使用情况以及雾化吸入类固醇、支气管扩张剂和口服皮质类固醇的使用情况。这些效果在治疗4年后明显，在治疗7年后更显著。
本研究强调了奥马珠单抗长期治疗对改善重度哮喘患者哮喘临床转归的作用。
